Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: normal saline solution placebo Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole

NCT02234570
View directory record Official record
Conditions
Neurocysticercosis
Interventions
Oxfendazole, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Not applicable Interventional

Effectiveness and Cost Study Comparing Two Ways to Deliver Albuterol for the Treatment of Asthma in the Hospital

NCT00623688
View directory record Official record
Conditions
Status Asthmaticus
Interventions
Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC), Airlife Sidestream High Efficiency Nebulizer
Device
Lead sponsor
Akron Children's Hospital
Other
Eligibility
12 Months to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Sep 23, 2026, 10:35 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Tolerability of AD-NP1 in Healthy Human Adult Volunteers

NCT07762001
View directory record Official record
Conditions
Maximum Tolerated Dose, Dose Escalation
Interventions
AD-NP1, Placebo
Drug
Lead sponsor
Arjun Deb, MD
Other
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

Clinical Trial to Evaluate the Safety and Analgesic Efficacy of VVZ-149 in Lumbar Radiculopathy (Sciatica)

NCT02644421
View directory record Official record
Conditions
Radiculopathy, Sciatica
Interventions
VVZ-149, Lidocaine, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2018 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

NCT06695130
View directory record Official record
Conditions
COVID-19 Immunization, Influenza Immunization
Interventions
RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1), RIV + rC19 (dose 2), RIV + rC19 (dose 3), RIV + rC19 (dose 4), Placebo (0.9% NaCl)
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • Cerritos, California • Vista, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

NCT01264783
View directory record Official record
Conditions
Myocardial Infarct
Interventions
RNS60, Placebo
Drug
Lead sponsor
Revalesio Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Brentuximab Vedotin for Systemic Sclerosis

NCT03222492
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
Interventions
Brentuximab Vedotin, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 23, 2026, 10:35 PM EDT
Active, not recruiting Phase 3 Interventional

Adjuvant Avelumab in Merkel Cell Cancer

NCT03271372
View directory record Official record
Conditions
Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8
Interventions
Avelumab, Peripheral Blood Collection, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
9
States / cities
Orange, California • Aurora, Colorado • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19

NCT04347239
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Placebo, Leronlimab (700mg)
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Alexander City, Alabama • Fullerton, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers

NCT01566877
View directory record Official record
Conditions
Marburg Hemorrhagic Fever
Interventions
AVI-7288, Placebo
Drug · Other
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

NCT01649765
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab 10 mg/kg, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 17 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
7
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 23, 2026, 10:35 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Angiotensin-(1-7) Cardiovascular Effects in Aging

NCT05301192
View directory record Official record
Conditions
Aging
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
65 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

ACAM 3000 MVA at Harvard Medical School

NCT00133575
View directory record Official record
Conditions
Smallpox
Interventions
MVA Smallpox Vaccine, Placebo, Live vaccinia virus vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 38 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2015 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Not applicable Interventional Results available

Antibiotic Irrigation for Pancreatoduodenectomy

NCT02186457
View directory record Official record
Conditions
Surgery, Infection
Interventions
Polymyxin B in Normal Saline, Placebo: Normal Saline
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 88 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1Phase 2 Interventional

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

NCT05683834
View directory record Official record
Conditions
Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus
Interventions
Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 25 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years

NCT00952419
View directory record Official record
Conditions
Influenza, Swine-origin A/H1N1 Influenza
Interventions
Monovalent Subvirion A/H1N1 Influenza vaccine, Normal saline solution (placebo)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 9 Years
Enrollment
474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
20
States / cities
Miami Beach, Florida • Marietta, Georgia • Woodstock, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 23, 2026, 10:35 PM EDT
Terminated Phase 2 Interventional Results available

Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma

NCT01727336
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma
Interventions
Dalantercept and axitinib, Placebo and axitinib
Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
36
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Sep 23, 2026, 10:35 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Wound Infiltration as Part of an Opioid Free Pain Management Pathway Following Cesarean Delivery

NCT03545516
View directory record Official record
Conditions
Pain, Postoperative, Anesthesia, Local, Opioid Use
Interventions
Bupivacaine, Dexmedetomidine, Placebo
Drug
Lead sponsor
Richmond University Medical Center
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 23, 2026, 10:35 PM EDT
Not listed Phase 2 Interventional

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

NCT05875948
View directory record Official record
Conditions
Hepatorenal Syndrome, Acute Kidney Injury
Interventions
R2R01, Terlipressin
Drug
Lead sponsor
River 2 Renal Corp.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Investigation of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty

NCT02569658
View directory record Official record
Conditions
Blood Loss, Anatomic Total Shoulder Arthroplasty, Reverse Total Shoulder Arthroplasty, Transfusion, Tranexamic Acid
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
Not listed
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

N-acetylcysteine and NMDA Antagonist Interactions

NCT00611897
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
N-acetylcysteine and ketamine, placebo and ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

NCT03834506
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Pembrolizumab, Docetaxel, Prednisone, Placebo, Dexamethasone
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Mobile, Alabama • Fullerton, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 23, 2026, 10:35 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT

NCT02815917
View directory record Official record
Conditions
D3 Dopamine Receptor, Cocaine-dependent, Healthy Volunteer
Interventions
[18F]FTP PET/CT
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 2 Interventional

Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

NCT01234558
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
GLYX-13
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2012 · Synced Sep 23, 2026, 10:35 PM EDT